

**What is claimed is:**

1. Oligodeoxynucleotides for stimulating an adjuvant or treating immune-related diseases, presented in General Formula:

5 [General Formula]: HKCGTTCRTGTCGSM (SEQ ID NO: 1)

wherein, R represents A or G; S represents C or G; H represents A, T or C; K represents G or T; and M represents C or A.

2. The oligodeoxynucleotides for stimulating an adjuvant or treating 10 immune-related diseases according to the claim 1,

wherein the oligonucleotides further comprise five nucleotides, presented in following General Formula, at a 5'-terminal end and a 3'-terminal end:

[General Formula]: DKMHKGTTCRTGTCGMYK (SEQ ID NO: 2)

wherein, R represents A or G; S represents C or G; H represents A, T or C; K represents G or T; D represents A, G or T; M represents C or A; M represents C or A; and Y represents C or T.

3. The oligodeoxynucleotides according to any of the claims 1 and 2,  
wherein the oligodeoxynucleotides protect normal immune cells when the 20 radiotherapy is applied.

4. The oligodeoxynucleotides according to any of the claims 1 and 2,  
wherein the oligodeoxynucleotides treat or prevent skin diseases.

5. The oligodeoxynucleotides according to any of the claims 1 and 2,  
wherein the oligodeoxynucleotides maintain balances of various Th1/Th2  
immune reactions.

5

6. The oligodeoxynucleotides according to any of the claims 1 and 2,  
wherein the oligodeoxynucleotides have a phosphodiester bond or  
phosphorothioate bond between the nucleotides.

10 7. The oligodeoxynucleotides according to any of the claims 1 and 2,  
wherein the oligonucleotides are selected from the group consisting of  
5'-AGCAGCGTTCGTGTCGGCCT-3' (SEQ ID NO: 3),  
5'-AGCAGCGTTCGTGTGCGCCT-3' (SEQ ID NO: 4),  
5'-AGCAGCGTTCATGTCGGCCT-3' (SEQ ID NO: 5),  
15 5'-AGCAGCGTTCGTGTCCGCCT-3' (SEQ ID NO: 6),  
5'-GTATCGTTCGTGTGTCGTCCT-3' (SEQ ID NO: 7) and  
5'-TGACTCGTTCGTGTGCGCATG-3' (SEQ ID NO: 8).